The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway
- 1 December 2008
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 295 (6), G1150-G1158
- https://doi.org/10.1152/ajpgi.90455.2008
Abstract
Cholangiocarcinomas are cancers that have poor prognosis and limited treatment options. The noncanonical Wnt pathway is mediated predominantly by Wnt 5a, which activates a Ca2+-dependent pathway involving protein kinase C, or a Ca2+-independent pathway involving the orphan receptor Ror2 and subsequent activation of Jun NH2-terminal kinase (JNK). This pathway is associated with growth-suppressing effects in numerous cell types. We have shown that anandamide decreases cholangiocarcinoma growth in vitro. Therefore, we determined the effects of anandamide on cholangiocarcinoma tumor growth in vivo using a xenograft model and evaluated the effects of anandamide on the noncanonical Wnt signaling pathways. Chronic administration of anandamide decreased tumor growth and was associated with increased Wnt 5a expression in vitro and in vivo. Treatment of cholangiocarcinoma cells with recombinant Wnt 5a decreased cell proliferation in vitro. Neither anandamide nor Wnt 5a affected intracellular calcium release, but both increased the JNK phosphorylation. Stable knockdown of Wnt 5a or Ror2 expression in cholangiocarcinoma cells abolished the effects of anandamide on cell proliferation and JNK activation. Modulation of the endocannabinoid system may be important in cholangiocarcinoma treatment. The antiproliferative actions of the noncanonical Wnt signaling pathway warrants further investigation to dissect the mechanism by which this may occur.Keywords
This publication has 52 references indexed in Scilit:
- Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factorDigestive and Liver Disease, 2008
- Opposing Actions of Endocannabinoids on Cholangiocarcinoma GrowthPublished by Elsevier BV ,2007
- FK506 Binding Protein 12/12.6 Depletion Increases Endothelial Nitric Oxide Synthase Threonine 495 Phosphorylation and Blood PressureHypertension, 2007
- Wnt/β-catenin signaling in cancer stemness and malignant behaviorCurrent Opinion in Cell Biology, 2007
- Filopodia formation mediated by receptor tyrosine kinase Ror2 is required for Wnt5a-induced cell migrationThe Journal of cell biology, 2006
- Diseases of Wnt signalingReviews in Endocrine and Metabolic Disorders, 2006
- A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiformeBritish Journal of Cancer, 2006
- Vascular Endothelial Growth Factor Stimulates Rat Cholangiocyte Proliferation Via an Autocrine MechanismGastroenterology, 2006
- γ-Aminobutyric Acid Inhibits Cholangiocarcinoma Growth by Cyclic AMP–Dependent Regulation of the Protein Kinase A/Extracellular Signal-Regulated Kinase 1/2 PathwayCancer Research, 2005
- VEGF as a Therapeutic Target in CancerOncology, 2005